Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19.
J Chin Med Assoc
; 83(8): 710-711, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-733327
ABSTRACT
The pandemic infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is widely increasing the patients affiliated with coronavirus disease 2019 (COVID-19) from last December of 2019. It is reported that the entry receptor of SARS-CoV-2 has been confirmed to be angiotensin-converting enzyme 2 (ACE2). Notably, whether the ACE-related inhibitors or drugs modulated ACE2 activity in affecting the viral activity and disease severity of SARS-CoV-2 is still an open question. Dipeptidyl peptidase-4 (DDP-4), a well-known anti-diabetic drug, has been widely used to control the glycemic condition in patients with diabetes. In this article, we are focusing on the impact of ACE inhibitors (ACEI) and DPP4 inhibitors used on SARS-CoV-2 activity and discussions about those drugs that may be related to infectious condition of COVID-19 diseases.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Diabetes Mellitus
/
Dipeptidyl-Peptidase IV Inhibitors
/
Betacoronavirus
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Chin Med Assoc
Journal subject:
Medicine
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS